Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Sanofi Ord Shs SNYNF

Healthcare

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood... see more

Add To Watchlist

Recent & Breaking News (OTCPK:SNYNF)

FDA Grants Breakthrough Therapy Designation for Genzyme's Olipudase Alfa

Business Wire June 4, 2015

Employers with Health Benefit Plans Question the Value of their Plans

Canada NewsWire June 3, 2015

Sanofi Announces Men With Advanced Prostate Cancer in England Will Continue to Have Access to Cabazitaxel (Jevtana®)

PR Newswire May 28, 2015

Genzyme Commemorates World MS Day with Awareness and Educational Events Globally

Business Wire May 27, 2015

Genzyme to Present Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab) Data at CMSC

Business Wire May 26, 2015

Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis

PR Newswire May 21, 2015

Genzyme's Announces Launch of Expression of Hope III Art Exhibit

Business Wire May 20, 2015

Genzyme Receives Innovation Award from the National Organization for Rare Disorders (NORD) for the Development of Cerdelga®

Business Wire May 19, 2015

Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the American Thoracic Society 2015 International Conference

PR Newswire May 18, 2015

Sanofi Exercises Option on Second Therapeutic Program with Selecta Biosciences to Develop an Antigen-Specific Immunotherapy Based on Synthetic Vaccine Particle Technology

Business Wire May 13, 2015

Singer and "Pretty Little Liars" Actress Lucy Hale Lends Her Voice to Voices of Meningitis(TM) to Help Improve Teen Booster Vaccination Rates

PR Newswire May 11, 2015

Majority of Canadians unprepared for an allergy emergency. Team Allerject educates to save lives

Canada NewsWire May 5, 2015

Sanofi Delivers Q1 2015 Business EPS Growth of 2.6% at CER and 12.8% on a Reported Basis

PR Newswire April 30, 2015

Sanofi Q1 2015 Results - Interview With CFO Jérôme Contamine

PR Newswire April 30, 2015

FDA Grants Fast Track Designation to Genzyme's Investigational Substrate Reduction Therapy for the Treatment of Fabry Disease

Business Wire April 28, 2015

Effect of Genzyme's Multiple Sclerosis Treatment Lemtrada® (alemtuzumab) on Slowing Brain Atrophy and MRI Lesion Activity Maintained Through Four Years

Business Wire April 23, 2015

National Access Project for Cancer Testing Gains Momentum

Business Wire April 21, 2015

Genzyme Initiates Phase 2a Clinical Trial to Evaluate Oral Therapy for Fabry Disease

Business Wire April 21, 2015

Genzyme to Present New Long-Term Data on Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab) at AAN

Business Wire April 13, 2015

Genzyme's Cerdelga® (eliglustat) Capsules Approved in Japan

Business Wire March 30, 2015